KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) EBT: 2019-2025

Historic EBT for Royalty Pharma (RPRX) over the last 7 years, with Sep 2025 value amounting to $444.2 million.

  • Royalty Pharma's EBT fell 44.91% to $444.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year decrease of 24.00%. This contributed to the annual value of $1.3 billion for FY2024, which is 21.72% down from last year.
  • Per Royalty Pharma's latest filing, its EBT stood at $444.2 million for Q3 2025, which was up 390.11% from $90.6 million recorded in Q2 2025.
  • Royalty Pharma's 5-year EBT high stood at $806.8 million for Q2 2021, and its period low was -$610.0 million during Q4 2022.
  • Moreover, its 3-year median value for EBT was $351.3 million (2023), whereas its average is $363.6 million.
  • As far as peak fluctuations go, Royalty Pharma's EBT slumped by 1,236.61% in 2022, and later skyrocketed by 10,243.53% in 2025.
  • Quarterly analysis of 5 years shows Royalty Pharma's EBT stood at $53.7 million in 2021, then slumped by 1,236.61% to -$610.0 million in 2022, then surged by 217.63% to $717.6 million in 2023, then tumbled by 53.41% to $334.4 million in 2024, then plummeted by 44.91% to $444.2 million in 2025.
  • Its EBT stands at $444.2 million for Q3 2025, versus $90.6 million for Q2 2025 and $433.4 million for Q1 2025.